Qiao Su

13 Liulin Road
Dayingmen, 300222, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Corrigendum to "Baseline metabolic signature predicts cognitive improvement and longitudinal glycerophospholipid shifts track recovery in first-episode drug-naïve schizophrenia" [Progress in Neuropsychopharmacology & Biological Psychiatry 148 (2026) 111830].

Corrigendum to "Baseline metabolic signature predicts cognitive improvement and longitudinal glycerophospholipid shifts track recovery in first-episode drug-naïve schizophrenia" [Progress in Neuropsychopharmacology & Biological Psychiatry 148 (2026) 111830].

Journal: Progress in neuro-psychopharmacology & biological psychiatry

Published: August 10, 2026

Baseline metabolic signature predicts cognitive improvement and longitudinal glycerophospholipid shifts track recovery in first-episode drug-naïve schizophrenia.

Baseline metabolic signature predicts cognitive improvement and longitudinal glycerophospholipid shifts track recovery in first-episode drug-naïve schizophrenia.

Journal: Progress in neuro-psychopharmacology & biological psychiatry

Published: May 29, 2026

Association between thyroid hormone T3 and aggression in drug-naïve schizophrenia: a directed acyclic graph analysis.

Association between thyroid hormone T3 and aggression in drug-naïve schizophrenia: a directed acyclic graph analysis.

Journal: European archives of psychiatry and clinical neuroscience

Published: March 04, 2026

Association between serum non-enzymatic antioxidants and cognitive impairment in drug-naïve patients with schizophrenia.

Association between serum non-enzymatic antioxidants and cognitive impairment in drug-naïve patients with schizophrenia.

Journal: BMC psychiatry

Published: February 03, 2026

Diagnosis-specific associations of plasma NGAL in drug-naïve schizophrenia and major depressive disorder: an exploratory cross-sectional study.

Diagnosis-specific associations of plasma NGAL in drug-naïve schizophrenia and major depressive disorder: an exploratory cross-sectional study.

Journal: BMC psychiatry

Published: December 01, 2025

Associations between plasma BDNF, VEGF, and EGF and cognition in drug-naïve schizophrenia with and without sleep disturbances.

Associations between plasma BDNF, VEGF, and EGF and cognition in drug-naïve schizophrenia with and without sleep disturbances.

Journal: European archives of psychiatry and clinical neuroscience

Published: November 07, 2025

Plasma biomarkers in drug-naïve schizophrenia with severe cognitive impairment via targeted metabolomics.

Plasma biomarkers in drug-naïve schizophrenia with severe cognitive impairment via targeted metabolomics.

Journal: Psychoneuroendocrinology

Published: August 19, 2025

The relationship between age of onset, peripheral plasma protein markers and social cognition in first-episode drug-naïve schizophrenia.

The relationship between age of onset, peripheral plasma protein markers and social cognition in first-episode drug-naïve schizophrenia.

Journal: Schizophrenia research

Published: June 06, 2025

The relationship between inflammation and cognitive function in drug-naïve schizophrenia with or without pre-metabolic syndrome.

The relationship between inflammation and cognitive function in drug-naïve schizophrenia with or without pre-metabolic syndrome.

Journal: Psychiatry research

Published: February 25, 2025

The multiomics landscape of plasma exosomes in first-episode drug-naïve of schizophrenia.

The multiomics landscape of plasma exosomes in first-episode drug-naïve of schizophrenia.

Journal: BMC psychiatry

Published: February 13, 2025

Sex differences in the relationship between the vascular endothelial growth factor and cognition in drug-naïve schizophrenia.

Sex differences in the relationship between the vascular endothelial growth factor and cognition in drug-naïve schizophrenia.

Journal: Schizophrenia research

Published: December 11, 2024

Prediction of treatment response in drug-naïve schizophrenia patients from the perspective of targeted metabolomics.

Prediction of treatment response in drug-naïve schizophrenia patients from the perspective of targeted metabolomics.

Journal: Schizophrenia research

Published: November 29, 2024

Showing 1-12 of 18

Last Updated: 09/26/2026